Home » Stocks » EBS

Emergent BioSolutions, Inc. (EBS)

Stock Price: $92.31 USD 1.44 (1.58%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $92.80 +0.49 (0.53%) Mar 5, 7:48 PM
Market Cap 4.92B
Revenue (ttm) 1.56B
Net Income (ttm) 305.10M
Shares Out 52.70M
EPS (ttm) 5.67
PE Ratio 16.28
Forward PE 12.02
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $92.31
Previous Close $90.87
Change ($) 1.44
Change (%) 1.58%
Day's Open 92.60
Day's Range 86.16 - 92.99
Day's Volume 726,433
52-Week Range 46.37 - 137.61

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
CNBC - 3 days ago

Emergent CEO Bob Kramer told CNBC that the company has infrastructure in place to produce Johnson & Johnson and AstraZeneca vaccines around the clock.

GlobeNewsWire - 6 days ago

GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the follow...

Forbes - 1 week ago

The stock price of Emergent Biosolutions, a biopharmaceutical company focused on vaccines and antibody therapeutics for infectious diseases, and opioid overdoses, has seen a 17% drop over the ...

24/7 Wall Street - 1 week ago

With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.

Other stocks mentioned: ANF, MAT, WDC, ALLK, EOLS, GBIO, RDUS, TRI
24/7 Wall Street - 2 weeks ago

With the trading day more than halfway over, the broad markets were sliding into the weekend.

Other stocks mentioned: CROX, M, CNA, MNTK, MOH, NMRK, NPTN
The Motley Fool - 2 weeks ago

An analyst downgraded the stock.

Zacks Investment Research - 2 weeks ago

Emergent's (EBS) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Sales of contract development and manufacturing services rise.

Benzinga - 2 weeks ago

Shares of Emergent BioSolutions (NYSE:EBS) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 133.76% over the past year to $3.6...

GlobeNewsWire - 2 weeks ago

GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2020. The Company also ...

The Motley Fool - 3 weeks ago

These stocks would be buys even without the pandemic.

Other stocks mentioned: PFE, REGN
GlobeNewsWire - 1 month ago

GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the fi...

Market Watch - 1 month ago

Shares of Humanigen Inc. were down 2.5% in trading on Monday after it announced a contract development and manufacturing deal with Emergent BioSolutions Inc. for its experimental COVID-19 trea...

Other stocks mentioned: HGEN
Business Wire - 1 month ago

GAITHERSBURG, Md. & BURLINGAME, Calif.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered i...

Other stocks mentioned: HGEN
Seeking Alpha - 1 month ago

Emergent BioSolutions remains well insulated from peers, with key COVID-19 vaccine drivers and exposure to adjacent specialty markets in public crises prevention. Additional drivers in contrac...

CNBC Television - 1 month ago

Emergent Biosolutions CEO discusses role in helping to bring coronavirus vaccines to market

Emergent Biosolutions CEO Bob Kramer joined Jim Cramer on "Mad Money" to give an update on the coronavirus vaccine manufacturing front.

Zacks Investment Research - 1 month ago

Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.

GlobeNewsWire - 1 month ago

GAITHERSBURG, Md., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced its financial forecast for 2021 and selected preliminary unaudited financial results ...

Zacks Investment Research - 1 month ago

Emergent Biosolutions (EBS) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Investment Research - 2 months ago

Emergent Biosolutions (EBS) closed the most recent trading day at $97.97, moving +1.01% from the previous trading session.

Zacks Investment Research - 2 months ago

Is (EBS) Outperforming Other Medical Stocks This Year?

The Motley Fool - 2 months ago

This biotech is about to tackle an enormous market opportunity as coronavirus vaccines receive regulatory clearance.

GlobeNewsWire - 2 months ago

GAITHERSBURG, Md., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the foll...

GlobeNewsWire - 2 months ago

GAITHERSBURG, Md. and NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate...

Zacks Investment Research - 3 months ago

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 3 months ago

Investors have been selling these stocks, but patient investors should take advantage of the opportunity.

Other stocks mentioned: CVS, FLGT
The Motley Fool - 3 months ago

Could these stocks be winners regardless of which coronavirus vaccine comes out on top?

Other stocks mentioned: COLD
Zacks Investment Research - 3 months ago

Is Emergent BioSolutions (EBS) a great pick from the value investor's perspective right now? Read on to know more.

The Motley Fool - 4 months ago

While profitability came in above estimates, the company missed big on the top line.

Zacks Investment Research - 4 months ago

Emergent (EBS) beats on earnings in Q3 while revenues miss estimates. Total product sales fall year over year and the company tightens its revenue guidance.

Seeking Alpha - 4 months ago

Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 6.83% and -14.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...

Zacks Investment Research - 4 months ago

On Emergent's (EBS) upcoming third-quarter earnings call, investors will focus on the company's recent CDMO collaborations to help partners manufacture a vaccine against COVID-19.

Zacks Investment Research - 4 months ago

Emergent Biosolutions (EBS) closed the most recent trading day at $90.77, moving -0.55% from the previous trading session.

Seeking Alpha - 4 months ago

Emergent BioSolutions has key niche differentiators that strengthen the operating model, with exposure to defence & public health threats. They hold the only FDA approved anthrax vaccine in th...

Zacks Investment Research - 4 months ago

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 4 months ago

Is (EBS) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 4 months ago

In the latest trading session, Emergent Biosolutions (EBS) closed at $99.55, marking a +1.86% move from the previous day.

Zacks Investment Research - 4 months ago

Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.

GlobeNewsWire - 4 months ago

GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the f...

The Motley Fool - 4 months ago

Blame it on Johnson & Johnson's pause of a late-stage study of its coronavirus vaccine candidate.

Zacks Investment Research - 4 months ago

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

Other stocks mentioned: CLLS, TMO, VRTX
The Motley Fool - 4 months ago

Forget politics and a pandemic. The outlook for these stocks keeps getting better, and analysts can't keep up.

Other stocks mentioned: DGX, REGN
GlobeNewsWire - 4 months ago

GAITHERSBURG, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of the Phase 3 clinical trial that will evaluate plasma-derived therap...

Zacks Investment Research - 5 months ago

Is (EBS) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 5 months ago

Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.

Other stocks mentioned: BGNE, HZNP, RGEN
Zacks Investment Research - 5 months ago

Emergent BioSolutions has been struggling lately, but the selling pressure may be coming to an end soon.

Forbes - 5 months ago

Emergent Biosolutions stock has rallied 111% since late March (vs. about 53% for the S&P 500) to its current level around $105.

Zacks Investment Research - 6 months ago

Is (EBS) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 6 months ago

In case of the S&P 500, whenever the index has gained more than 5% in August, September gains averaged 1.4%.

Other stocks mentioned: AAWW, DQ, ETSY, STMP
Zacks Investment Research - 6 months ago

Strong economic data and positive developments in coronavirus vaccine trials have helped stocks overcome the coronavirus slump. Here are five stocks that can make the most

Other stocks mentioned: AZPN, DKS, DY, HOME

About EBS

Emergent BioSolutions, a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a chol... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Nov 15, 2006
CEO
Robert Kramer
Employees
2,200
Stock Exchange
NYSE
Ticker Symbol
EBS
Full Company Profile

Financial Performance

In 2020, EBS's revenue was $1.56 billion, an increase of 40.63% compared to the previous year's $1.11 billion. Earnings were $305.10 million, an increase of 459.82%.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for EBS stock is "Buy." The 12-month stock price forecast is 118.50, which is an increase of 28.37% from the latest price.

Price Target
$118.50
(28.37% upside)
Analyst Consensus: Buy